The Xu＇s chart for prostate biopsy： a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer

作     者：Jianfeng Xu 

作者机构：Fudan institute of Urology Huashan Hospital Shanghai State Key Laboratory of Genetic Engineering School of Life Science Shanghai School of Public Health Fudan University Shanghai China Center for Cancer Genomics Wake Forest School of Medicine. Winston-Salem. North Carolina. USA. 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2014年第16卷第4期

页      面：536-540页

核心收录：

学科分类：090603[农学-临床兽医学] 0710[理学-生物学] 1002[医学-临床医学] 07[理学] 09[农学] 0906[农学-兽医学] 071007[理学-遗传学] 

基　　金：I thank for the contributions of study populations, data analysis and discussion to this paper from Drs S Lilly Zheng and lielin Sun from Wake Forest School of Medicine Dr Henrik Gronberg from Karolinska Institutet of Sweden Mr Haitao Chen from School of Life Science, Fudan University, China Dr Qiang Ding, Ms Fang Liu and Xiaoling Lin from Fudan Institute of Urology, Fudan University, China Drs Yinghao Sun, Shangchen Ren and Zhensheng Zhang from Changhai Hospital, China and Dr Donna P Ankerst from Technical University Munich, Germany. This work was partially funded by the National Key Basic Research Program Grant 973 （No. 2012CB518301）, the Key Project of the National Natural Science Foundation of China （No. 81130047）, intramural grants from Fudan University and Huashan Hospital and the National Institutes of Health （No. NCI CA 129684）. 

主　　题：MOLECULAR URINE TEST 5 GENETIC-VARIANTS MULTICENTER EVALUATION RISK PCA3 MEN PREDICTION MARKERS SERUM SCORE 

摘      要：Elevated serum prostate-specific antigen （PSA） level is the primaryindication for prostate biopsy for detection of prostate cancer （PCa） in the modern era. The detection rate of PCa from biopsy is typically below 30%, especially among patients with PSA levels at 4-10 ng ml-1. In the past several years, additional biomarkers, such as Prostate Health Index, PCA3 and genetic risk score （GRS） derived from multiple PCa risk-associated single nucleotide polymorphisms （SNPs） have been shown to provide added value to PSA in discriminating prostate biopsy outcomes. However,